Role of Inflammasomes in COVID-19 Disease

COVID-19 by SARS-CoV-2 Infection Clinical Trial

— CoVInnate  

Official title:

Role of Inflammasomes in COVID-19 Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04385017
• Other study ID #: 20-PP-07
• Status: Completed
• Phase: N/A
• Start date: May 11, 2020
• Est. completion date: December 30, 2022

Study information

• Verified date: October 2022
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As of March 25, 2020, 414,179 cases and 18,440 deaths secondary to Coronavirus 2019 disease (COVID-19) have been reported worldwide. The unfavorable course of the patients is characterized on the immunological level by an intense pro-inflammatory response which can go as far as a cytokinic storm. This pandemic affects a naive world population from an immunological point of view with respect to SARS-CoV-2 responsible for COVID-19. The evolution is favorable without hospitalization in almost 85% of cases. Among patients hospitalized for pneumonia, some will not require ventilatory support while others will need intensive care. To date, two main types of unfavorable evolution have been described. The first is a bi-phasic evolution beginning with a paucisymptomatic form which is worsened secondarily with respiratory distress associated with a decrease in the viral load in the airways. The second is associated with persistent high viral loads in the airways and detection of the virus in the blood. These different clinical profiles could depend on the quantitative and qualitative response of the innate immune system.

At the early stage of a viral infection the innate immunity is capable of detecting certain conserved microbial patterns (PAMP, pathogen-associated molecular pattern) recognized by receptors dedicated to these patterns (PRR, pattern recognition receptor). This process allows to initiate the pro-inflammatory response via different signaling pathways.

Activating multiprotein complexes called inflammasomes, which cause pro-IL-1β and pro-IL-18 to be transformed into active pro-inflammatory cytokines are one of these pathways.

The central role of inflammasomes in the secretion of these pro-inflammatory cytokines deserves an in-depth study of their activation during COVID-19, whereas the inadequate inflammatory response appears to be the determining factor in the unfavorable development of patients.

The objective of this project is to analyze the level of activation of the inflammasomes and then to search for inactivating or activating mutations among the genes which code for the proteins constituting the inflammasomes in Covid-19 patients. The identification of mutations in patients with a serious clinical presentation or even death would be followed by fundamental work by analyzing in a cellular model the impact of these mutations on the secretion of IL-1β.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: December 30, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age above 18 years old. SARS-CoV-2 infection confirmed by RT PCR or by serology Hospitalised patients with less than 14 days of COVID-19 symptoms. Date of first symptom being defined as to the date of one of the following symptoms : cough, dyspnea, fever above 38 °C, anosmia, dysgeusia or ageusia, chilblain Lupus erythematous Women of fertile age using at least one contraceptive method Health insurance Written informed consent

Exclusion criteria

• Pregnant or breastfeeding female

• Human immunodeficiency virus infection with CD4 under 200 cell/mm3

• Aplasia

• at-risk patients (minor, patient under judicial protection or tutorship)

Related Conditions & MeSH terms

• COVID-19
• COVID-19 by SARS-CoV-2 Infection

Intervention

Other:
• COVID-19 patients
It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing

Locations

Country	Name	City	State
France	Ch Cannes, Réanimation	Cannes	Alpes Maritimes
France	CHU de nice	Nice	Alpes-Maritimes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19	Percentage of immune cells with inflammasome positive labeling using flow cytometry in comparison to controls	At inclusion
Secondary	Genes nucleoside polymorphism analysis	Identification of genes nucleotide polymorphisms by Whole Exome Sequensing and bioinformatics analysis. Analysis of activating or inactivating mutations of NLRP3 NLRC4 AIM2 and Pyrin inflammasomes in patients with severe COVID-19.	At inclusion